AFFIRM Articles

Articles

#AUA14 - Poster: An indirect treatment comparison and cost-effectiveness analysis of abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer post chemotherapy

ORLANDO, FL USA (UroToday.com) - Presented by Melissa Thompson,¹ Tracy Li,² Mary B. Todd,² Margaret K. Yu,⁴ Thian Kheoh,³ Jianming He,² and Ryan Saadi² at the American Urological Association (AUA) Annual Meeting - May 16 - 21, 2014 - Orlando, Florida USA

Published May 21, 2014
ASCO 2013 - Slide Lecture: Effect of corticosteroid use at baseline on overall survival in patients receiving abiraterone acetate: Results from a randomized study (COU-AA-301) in metastatic castration-resistant prostate cancer post-docetaxel

CHICAGO, IL USA (UroToday.com) - Presented by Bruce Montgomery,¹on behalf of Thian Kheoh,² Arturo Molina,² Jinhui Li,³ Joaquim Bellmunt,⁴ Charles J. Ryan,⁵ NamPhuong Tran,² Yohann Loriot,⁶ Eleni Efstathiou,⁷ Howard I. Scher,⁸ Johann S. de Bono⁹ at the American Society of Clinical Oncology (ASCO) Annual Meeting - May 31 - June 4, 2013 - McCormick Place - Chicago, IL USA

Published June 17, 2013